ClinicalTrials.gg
Not yet recruitingNCT06608329Updated Sep 23, 2024

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

A Phase 1 interventional study of HDM1002 in Healthy Adult Subject, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the effect of formulation on relative bioavailability of HDM1002, and the food effect on pharmacokinetics of HDM1002.

02

Conditions studied

  • Healthy Adult Subject

Keywords

  • HDM1002 tablet
  • Glucagon-Like Peptide-1 Receptor Agonists
03

In context

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. According to the medical history, clinical laboratory test results, vital sign measurements, 12 lead results, and physical examination results during the screening period, the investigator considers the subject to be in good general health.
  2. Age range of 18-45 years old (including range), no limit to gender.
  3. Male subject weighed ≥50.0 kg, female subject weighed ≥45.0 kg, and a (BMI) within the range of 19.0 - 30.0 kg/m2 (including cut-off values).
  4. Female subject of childbearing potentiaafter last dose, who have no childbearing plans and agrl during signature ICF to 30 days after last dose and male subject during signature ICF to 90 days ee to use highly effective and consent not to donate sperm and oocyte during this period.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history or family history of medullary thyroid cancer, thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2), or calcitonin≥50 ng/L during the screening period.
  2. History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening.
  3. History of acute cholecystitis attack within 3 months prior to screening.
  4. Subject judged by investigator has dysphagia, diseases or conditions that affect gastric emptying, or affect the absorption of gastrointestinal nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, etc.
  5. History of previous surgery that will affect the absorption, distribution, metabolism, and excretion of drugs or plan to undergo surgery during the study period.
  6. During screening period, any abnormalities in physical examination, , laboratory tests, and vital signs which are of .
  7. Taken or planned to take any drug that effect liver enzyme or transporter activity within 28 days prior to taking the drug.
  8. History of clinically significant cardiovascular and cerebrovascular disease within 6 months prior to screening or at the time of admission.
  9. Presence of clinically significant ECG results judged by the investigator at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Period 1: Subjects received HDM1002 table (200 mg×1)in fasted state; Period 2: Subjects received HDM1002 tables (100 mg×2)in fasted state; Period 3: Subjects received HDM1002 table (200 mg×1)in fed state.

    Drug: HDM1002

  • Experimental
    Cohort 2

    Period 1: Subjects received HDM1002 tables (100 mg×2)in fasted state; Period 2: Subjects received HDM1002 table (200 mg×1)in fed state; Period 3: Subjects received HDM1002 table (200 mg×1)in fasted state.

    Drug: HDM1002

  • Experimental
    Cohort 3

    Period 1: Subjects received HDM1002 table (200 mg×1)in fed state; Period 2: Subjects received HDM1002 table (200 mg×1)in fasted state; Period 3: Subjects received HDM1002 tables (100 mg×2)in fasted state.

    Drug: HDM1002

Interventions

  • Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.

06

What researchers measure

Primary outcomes

  1. AUC[0-∞]

    Area under the curve from time 0 hour to ∞

    Time frame: Day1-Day17

  2. AUC[0-t]

    Area under the curve from time 0 to t hour

    Time frame: Day1-Day17

  3. Cmax

    Maximum observed concentration

    Time frame: Day1-Day17

  4. Tmax

    Time to maximum plasma concentration

    Time frame: Day1-Day17

  5. t1/2

    Half life

    Time frame: Day1-Day17

  6. CL/F

    Apparent Clearance

    Time frame: Day1-Day17

  7. Vz/F

    Apparent volume of distribution

    Time frame: Day1-Day17

  8. F

    Relative Bioavailability

    Time frame: Day1-Day17

Secondary outcomes

  1. Adverse events (AEs)

    Number of subjects reporting AEs

    Time frame: Day1-Day17

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Nov 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Sep 23, 2024
StartEst.
Oct 2024
Primary completionEst.
Nov 2024
CompletionEst.
Dec 2024
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06608329
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Oct 2024 (estimated)
Primary completion
Nov 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Sep 23, 2024

Study contacts

Ying Wang
Contact
nancywangying@163.com
+86-18367124548

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion